HYTN announced that it has received a new set of import permits from the United Kingdom's Home Office and corresponding export permits from Health Canada. These permits enable the fulfillment of international orders totaling over 400 kilograms of Good Manufacturing Practice (GMP) cannabis products, advancing HYTN's global reach and operational capabilities.
"HYTN consistently meets the standards of the European Pharmacopoeia and the German Pharmacopoeia (Deutsches Arzneibuch, DAB) reflecting our dedication to quality and global expansion," states Jason Broome, Chief Operating Officer of HYTN. "With GMP systems and an efficient operational model, we are ready to meet the rising global demand for pharmaceutical-grade cannabis products."
The Company expects to complete all shipments permitted by these permits by the end of Q1 2025, highlighting its ability to meet international demand on schedule.
For more information:
HYTN Innovations
hytn.ca/